Financière de Tubize SA - Revision history

95.149.241.133 at 23:03, 19 August 2022

2022-08-19T23:03:29Z

← Older revision		Revision as of 00:03, 20 August 2022
Line 2:		Line 2:

	Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.		Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.

			__INDEX__

109.180.50.163 at 20:32, 12 August 2022

2022-08-12T20:32:25Z

← Older revision		Revision as of 21:32, 12 August 2022
Line 1:		Line 1:
			== Summary ==

	Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.		Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.

>Paris: Created page with "Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for..."

2022-08-06T00:41:05Z

Created page with "Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for..."

New page

Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.